MM

Maitreya Medica.

Q2 FY26

Maitreya Medica. Q2 FY26 investor presentation: Revenue & Margins

Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹127

Market cap₹86 Cr

Updated16 Oct 2026

Read3 min read

Based on Maitreya Medica.'s Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentationreports, not management guidance.

The short version

Revenue till Sept 2025 (H1) reported at Rs. EBITDA (Till Sept 2025): 0.0360 Cr Loss (Page 26) - Operating Margin: Not explicitly stated in the presentation.

From Maitreya Medica.'s Q2 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Revenue till Sept 2025 (H1) reported at Rs. 23.92 crore (Page 26).
EBITDA shows a small loss of Rs. 0.036 crore for the same period (Page 26).
No explicit year-on-year revenue or sales growth percentage is stated in the presentation.
Management comments indicate units "started showing promising revenues" with hopes to recover in the coming half (Page 6).
New hospital unit in Valsad planned to commence operations from December 2025, expected to contribute to revenue (Page 20).

2 more points from Maitreya Medica.'s call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

EBITDA (Till Sept 2025): 0.0360 Cr Loss (Page 26)
Operating Margin: Not explicitly stated in the presentation.
Profit After Tax (PAT): Negative (loss), exact figure not provided; mention of PAT negative due to Rs. 1.70 Cr bad debts adjustment (Page 6).

- **Year-on-Year Change**: Not explicitly quantified in percentage terms; management notes revenue growth from expansions but profits impacted by one-time bad debts adjustment (Page 6). - **Margin Outlook**: No explicit margin outlook given; management expects upcoming units and recent expansions to improve revenues and help recover profitability in the second half of the year (Page 6). Summary: The presentation reports a loss at EBITDA and PAT levels for the quarter till Sept 2025, with operational pressures due to expansion and a one-time bad debts adjustment but expresses optimism on revenue and profit recovery ahead.

2 more points from Maitreya Medica.'s call on margins

Pro opens every point from 15K+ earnings calls

See what Maitreya Medica. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

New Hospital at Valsad, Gujarat (Maitreya Hospital Private Limited, Subsidiary)
Recently received Building Usage Permission.
Planned capacity: 125 beds.
Facilities: 3 modular operation theatres, 20-bed ICU, 6-bed Dialysis unit.
Specialized services: cardiology and neurosurgery.
Expected to be fully operational starting December 2025.
Expansion Strategy
Focus on Gujarat and Maharashtra regions by locating hospitals in multiple cities/towns (Surat, Valsad, Mumbai).
Aims for increased capacity and accessibility.
Tulip Health Check (Subsidiary)
50-bed capacity.
Shifted to new premises and functional.
KLS Memorial Hospital, Mumbai
70-bed capacity.

2 more points from Maitreya Medica.'s call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

The investor presentation does not explicitly mention any new fundraising through debt or equity.
There is no specific mention of any change in borrowings or net debt in the provided content.
The presentation highlights investments made in doctors, equipment, technology, administration, and staff as part of expansion efforts, leading to increased short-term costs.

2 more points from Maitreya Medica.'s call on fundraising

Pro opens every point from 15K+ earnings calls

See what Maitreya Medica. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not report any information regarding order book, order inflow, or pending orders. It focuses on: - Financial performance including revenue and EBITDA (e.g. Rs. 23.92 Cr revenue till Sept 2025), - Hospital portfolio and capacity details, - Industry growth outlook, - Segmental services in demand,

2 more points from Maitreya Medica.'s call on order book

Pro opens every point from 15K+ earnings calls

What Maitreya Medica.'s management said in earlier quarters

Others in Healthcare Services this season

Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
3B Blackbio (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
Unihealth Hosp (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Indegene Ltd (Q2 FY26)
Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term…

Compare:vs Apollo Hospitals vs Manipal Health Enterprises Ltd vs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Maitreya Medica. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Maitreya Medica. Q2 FY26 results?

Revenue till Sept 2025 (H1) reported at Rs. EBITDA (Till Sept 2025): 0.0360 Cr Loss (Page 26) - Operating Margin: Not explicitly stated in the presentation.

What is Maitreya Medica. share price analysis?

Maitreya Medica. currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹86 Cr. Investors should review the full earnings analysis for detailed insights.

Is Maitreya Medica. planning capital expenditure?

New Hospital at Valsad, Gujarat (Maitreya Hospital Private Limited, Subsidiary) - Recently received Building Usage Permission.

Keep Maitreya Medica. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.